Tmax in three treatment, three period, three sequence design [Nonparametrics]

posted by libaiyi – China, 2019-04-09 07:15 (741 d 03:24 ago) – Posting: # 20134
Views: 1,862

Dear all,

I have a question about Wilcoxon signed rank test on Tmax. In a three treatment, three period, three sequece design (two test formulations and one reference formulation with the sequences as T1-R-T2, R-T2-T1, and T2-T1-R), can we use Wilcoxon signed rank test for Tmax? If not, what can we do to statistically evaluate Tmax?

Thanks in advance!

Best,

Libaiyi

Complete thread:

Activity
 Admin contact
21,419 posts in 4,475 threads, 1,510 registered users;
online 3 (0 registered, 3 guests [including 1 identified bots]).
Forum time: Monday 10:39 CEST (Europe/Vienna)

There is one certainty in drug development
and statistics that one can depend on:
the data are always late.    Scott Patterson and Byron Jones

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5